Short answer
Keros Therapeutics, Inc. (KROS) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$29M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY · −100.0% QoQ
- Net income
- −$29M
- +6.5% YoY · −21.1% QoQ
- EPS (diluted)
- −$1.45
- −90.8% YoY · −19.8% QoQ
Source: XBRL data from the Keros Therapeutics, Inc. (KROS) Q2 2026 10-Q on SEC EDGAR. USD.
Keros Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0 vs $18.2M YoY, down $18.2M from Takeda service revenue
- Net loss $28.7M vs $30.7M YoY; operating loss $30.9M vs $39.8M
- Rinvatercept R&D $4.1M, up $2.7M; elritercept $14K, down $15.6M
- Cash and equivalents $257.6M as of June 30, 2026
- Near-term headwinds: inflation, higher rates, tariffs, supply-chain constraints and geopolitical uncertainty
Risk Factors
- Net loss $52.4 million for six months ended June 30, 2026, with accumulated deficit of $534.2 million
- Cash $257.6 million, expected to fund operations into first half of 2028
- Clinical-trial risk heightened by prior TROPOS termination after pericardial effusion safety events
- Regulatory approval risk from FDA disagreement over trial design, endpoints, or clinical-data interpretation
- Near-term execution risk from Phase 2 rinvatercept trials in Duchenne muscular dystrophy and planned ALS initiation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Keros Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.